Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

Original reporting
Published Nov 10, 2026, 7:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 7:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hemab (COAG) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$COAGBullishMed
01

Why it matters

The disclosed trial milestones represent the first public disclosure of pivotal data, which can materially affect the stock price.

02

Market read

First report of pivotal trial initiation and early Phase I data provides a fresh catalyst for COAG, likely prompting short‑term trading interest.

03

What to watch

Potential regulatory delays or competition from other hemostasis therapies.

Relevance 8/10Novelty 8/10Timing: mid-2027 data release

Background

Hemab (COAG) held its Q3 2026 earnings call, providing updates on three clinical programs and announcing a new board member.

Company-level read

Ticker impact

$COAGBullishHigh confidence
Context

Hemab disclosed initiation of its pivotal Phase III SOLARA trial and first-in-human dosing for HMB-003, plus Phase I/II data for its other programs.

Expected impact

likely upward pressure as the market prices in the pivotal trial initiation

Evidence & confidence

First report of a Phase III trial and early Phase I data are material biotech catalysts that typically drive short‑term price gains.

Market effects

Advances in rare‑bleeding disorder therapeutics could benefit the broader biotech sector focused on hematology.

US biotech investors may see increased interest in rare‑disease pipelines.

Limited to investors tracking niche biotech developments.

Counterpoint

If trial data later show safety concerns, the initial hype could reverse sharply.

Key entities

  • Hemab

    Biotech company developing treatments for rare bleeding disorders.

  • Keli Walbert

    New board member with commercial leadership experience.

Related articles

$COAGMed

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA

Hemab Therapeutics (COAG) discussed its SOLARA Phase III trial and HMB002 data in its Q3 2026 earnings call. CEO Benny Sorensen highlighted a 50%+ reduction in annualized treated bleed rate for von Willebrand disease, with data covering Type 1 and 2A patients. The trial requires a minimum annualized treated bleed rate of four at entry. HMB002 aims to correct underlying pathophysiology and is monitorable by clinicians.

$COAGMedAI 8/10

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

High

Why is Hemab Therapeutics stock sliding today?

Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.

Med

Hemab Therapeutics Posts Q3 2026 Net Loss of $27.3 Million

Hemab Therapeutics reported a Q3 2026 net loss of $27.3M, up from $17.1M a year earlier, due to increased R&D and administrative expenses. The company had $430.2M in cash and expects it to last until 2029. Key developments include a Phase 3 trial launch for sutacimig and a Phase 1 trial for HMB-003.

$COAGMedAI 8/10

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A

$COAGMedAI 8/10

Hemab Begins Pivotal Study Of Potential Preventive Treatment For Glanzmann Thrombasthenia

Hemab Therapeutics (COAG) initiated a Phase 3 trial (SOLARA) for sutacimig, a potential preventive treatment for Glanzmann thrombasthenia (GT). The study aims to enroll 75 participants, with primary endpoint comparing treated bleed rates during treatment vs. run-in period. Sutacimig has received Fast Track, Orphan Drug, and Breakthrough Therapy designations from the FDA. COAG stock is currently trading at $46.30, down 5.55%.